AbbVie, Allmirall, Amgen, Celgene, Centocor, Eli Lilly, Galderma, Jansen Cilag, LEO Pharma, Mitsubishi, Novartis, Pfizer, Philips and Sandoz. K. Reich has received honoraria as a speaker and consultant for and participated in clinical trials sponsored by Abbott, Biogen-Idec, Centocor, Janssen-Cilag, Schering-Plough and Wyeth. A. Kavanaugh has served as an investigator for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen and UCB. H. Bachelez has served as a consultant for AbbVie, Almirall, Amgen, Boehringer, Celgene, Centocor, Eli Lilly, Janssen-Cilag, LEO Pharma, MSD, Merck-Serono, Novartis, Pfizer, Sandoz and Takeda. J. Barker has acted as consultant for or spoken at sponsored symposia for or received grant funding from AbbVie, Amgen, Celgene, Centocor, Eli Lilly, Janssen, Merck, Novartis and Pfizer. G. Girolomoni has received honoraria as a speaker and/or consultant by AbbVie, Actelion, Boehringer Ingelheim, Celgene, Dompè, Eli Lilly, Galderma, Janssen, LEO Pharma, Maruho, Merck-Serono, MSD, Mundipharma, Novartis, Otsuka, Pfizer, Rottapharm and Shiseido. R.G. Langley has served as principal investigator for and is on the scientific advisory board of Abbott, Amgen, Centocor and Schering-Plough. C.F. Paul has served as an investigator or consultant for Abbott, Amgen, Astellas, Celgene, Janssen-Cilag, LEO Pharma, Novartis, Pfizer and Pierre Fabre. L. Puig has served as a consultant and/or paid speaker for and/or participated in clinical trials for Abbott, Amgen, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Merck, MSD, Novartis and Pfizer. M.G. Lebwohl has served as an investigator for Amgen, Celgene, Coronado Biosciences, Eli Lilly, Janssen Biotech, LEO Pharma, GlaxoSmithKline and Ranbaxy, and as a consultant for Abbott, Amgen, Anacor, BioLineRx, Celgene, DermiPsor, Eli Lilly, Galderma, Janssen Biotech, LEO Pharma, Maruho Co., Meda, Novartis, Pfizer and Valeant. Available literature on psoriasis and psoriatic arthritis (PsA) demonstrates a tremendous burden of disease and suggests underdiagnosis and undertreatment. To obtain real-world physician perspectives on the impact of psoriasis and PsA and its treatment on patients' daily lives, including perceptions of, and satisfaction with, current therapies.The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) surveyed dermatologists (n = 391) and rheumatologists (n = 390) in North America (Canada and the United States) and Europe (France, Germany, Italy, Spain and United Kingdom). Dermatologists classified 20.3% and 25.7% of their patients as having severe psoriasis and severe PsA respectively; rheumatologists indicated that 48.4% of their PsA patients had active disease. Of the psoriasis patients complaining of joint pain, only 33.0% had a diagnosis of PsA. An impact on daily activities or social/emotional well-being was recognized by 57.2% to 79.3% of physicians. In patients with moderate-to-severe psoriasis, dermatologists reported 74.9% were receiving topical therapy, 19.5% conventional oral therapy and 19.6% biologics. Dermatologists and rheumatologists reported similar rates of topical (≈45%) and biologic (≈30%) therapy utilization for their PsA patients; conventional oral therapy was more often prescribed by rheumatologists (63.4%) vs. dermatologists (35.2%). Reasons for not initiating or maintaining systemic therapies were related to concerns about long-term safety, tolerability, efficacy and costs (biologics). Physicians in North America and Europe caring for patients with psoriasis and PsA acknowledge unmet treatment needs, largely concerning long-term safety/tolerability and efficacy of currently available therapies; evidence suggests underdiagnosis of PsA and undertreatment of psoriasis among dermatologists. Current published estimates of the worldwide prevalence of psoriasis range from approximately 1–3%.1-6 Psoriatic arthritis (PsA) occurs in approximately 10–30% of psoriasis patients. In the vast majority of cases, joint involvement follows skin involvement, often by 10 years.7, 8 Patients with psoriasis and PsA experience a significant burden of disease, including reduced quality of life, decreased physical function and increased comorbidities.7, 9, 10 Available evidence suggests that numerous unmet needs exist in the care of these patients, including underdiagnosis2, 7 and suboptimal treatment.11-13 Available surveys offer insight into psoriasis and PsA disease burden and treatment. However, most are limited to a specific geographic region, patients currently under the care of a physician and/or being treated in a specific healthcare setting and/or members of a patient association, or lack of both a patient and physician survey component. Moreover, many surveys provide limited information on patient- and physician-related factors influencing treatment decisions.To better